In March 2023 the Company received feedback from the FDA pertaining to its clinical development plans and intent to proceed with a mul-site Phase 2 study in the U.S. The Phase 2 study will be used to opmize dose and imaging schedules as well as explore various endpoints for clinical validity.
In March 2023 the Company received feedback from the FDA...
Add IBX (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
8.2¢ |
Change
0.000(0.00%) |
Mkt cap ! $2.677M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 10941 | 8.2¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 8.5¢ | 305 | 1 |
View Market Depth
| Last trade - 16.12pm 09/07/2024 (20 minute delay) ? |
| IBX (ASX) Chart |
Day chart unavailable